Founders of CardioPrecision Ltd, the global leader in transcervical access for the treatment of structural heart disease and cardiothoracic intervention, received the closely coveted and prestigious Cutler’s Surgical Prize.

CardioPrecision Founders Dr Ying Sutherland, PhD, and Mr Fraser Sutherland, MD, are honoured with award of the prestigious Cutler’s Surgical Prize by the Worshipful Company of Cutlers’ in association with The Royal College of Surgeons of England for their winning paper entitled “New Technology & Surgical Technique for Surgical Exposure of the Aorta and Aortic Valve for SAVR and TAVI: CoreVista® Retractor”. The award was made at a dinner held in their honour at Cutler’s Hall, London on Wednesday, March 13, 2019.

About CardioPrecision Ltd

CardioPrecision Ltd, based in Glasgow, UK is the global leader in transcervical access for the treatment of structural heart disease and cardiothoracic intervention. CardioPrecision’s CoreVista® Retractor and Accessories allow cardiothoracic surgery to be performed through a short incision in the skin crease of the neck. CardioPrecision is dedicated to making patients’ lives better through the development of innovative, less invasive access solutions for cardiothoracic surgery and cardiovascular intervention. For more information, visit

About Cutler’s Surgical Prize

The Cutlers’ Surgical Prize was instituted in 1981 and has become established as one of the most prestigious annual prizes for original innovation in the design or application of surgical instruments, equipment or practice to improve the health and recovery of surgical patients. It consists of an elegant mounted Victorian silver-gilt medal, together with an award to the winner or winning team. Each year The Royal College of Surgeons of England, in conjunction with The Cutlers’ Company, choose a surgeon (or a team including a surgeon) who has performed outstanding work in the field of technical advances in surgical treatment utilising modern technologies. The presentation is made at a dinner held at Cutlers’ Hall. For more information, visit

This news release includes forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding expected product benefits, anticipated product approvals, future plans related to the product lines, the benefits of the transaction, including future financial and operating results, objectives and expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of the company and are subject to significant risks and uncertainties.

Actual future events or results may differ materially from these statements as a result of various factors, including: unexpected costs of device development and approvals, unanticipated outcomes after more expanded pre-clinical and clinical experience with the devices, unexpected changes or delays related to product supply, potentials for unexpected regulatory or quality delays or developments, competitive dynamics, global economic conditions and customer acceptance, and other economic, business, and/or competitive factors. The forward-looking statements speak only as of the date of this communication. Except as required by law, The Company undertakes no obligation to update these statements.

CoreVista is a trademark of CardioPrecision Ltd.